- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions
- Tradjenta now available in U.S. pharmacies
- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- Novo Nordisk wins 2010 Good Design Award for NovoPen Echo
INDIANAPOLIS — A diabetes drug made by Eli Lilly and Amylin Pharmaceuticals has received approval from the Food and Drug Administration for use with an insulin product made by Sanofi.
Lilly and Amylin said Byetta (eventide) won approval from the FDA as an add-on therapy for patients with Type 2 diabetes taking Sanofi's Lantus (insulin glargine [rDNA origin]) who have not achieved adequate blood sugar control on Lantus alone.
"This expanded use for Byetta is important for clinical care in that it provides a new option for the many patients with Type 2 diabetes who are not achieving treatment goals," University of North Carolina School of Medicine professor John Buse said on behalf of Lilly and Amylin. "Byetta is well-suited for use with insulin glargine, offering a simple fixed-dose regimen that can help improve control of blood sugar overall and after meals."